Managing diabetes can often feel like a full-time job. Between monitoring blood sugar, planning meals, and staying active, there is a lot to juggle. That’s why having more accessible, high-quality medication options is so important.
Recently, the FDA approved a brand-new option for people who use mealtime insulin. It’s called Garzulys (insulin aspart-fsan), and it represents another major step forward in creating affordable, reliable choices for diabetes care.
But what exactly is Garzulys, and how does it compare to the insulin you might already be using? Let’s break it down so you can feel confident and informed.
Garzulys is a rapid-acting human insulin analog. In plain English, this means it is a fast-acting insulin designed to help control your blood sugar spikes right around mealtime.
Specifically, Garzulys was approved in July 2026 as a biosimilar to the popular branded insulin NovoLog® (insulin aspart). It is the third FDA-approved biosimilar to NovoLog to hit the market (following Merilog and Kirsty).
What is a biosimilar?
You can think of a biosimilar in much the same way you think of a generic drug, but for biologic medications (medicines made from living organisms). Because biologics are highly complex, exact copies can't be made. Instead, the FDA approves biosimilars that are "highly similar" to the original brand-name drug. This means Garzulys provides the exact same clinical benefits, safety, and effectiveness as NovoLog, with no clinically meaningful differences.
When you have diabetes, your body either doesn't make enough insulin or can't use it properly. This causes your blood sugar to rise, especially after you eat.
Because Garzulys is a rapid-acting insulin, it gets to work fast:
Note: Because it works so quickly, it is generally paired with a long-acting (basal) insulin that keeps your blood sugar stable between meals and overnight.
Garzulys is incredibly versatile. It is FDA-approved to improve glycemic (blood sugar) control in both adults and pediatric patients with diabetes mellitus.
Whether you manage Type 1 diabetes (where insulin therapy is an absolute requirement) or Type 2 diabetes (where insulin may be needed if diet, exercise, and other medications aren't quite enough), Garzulys is designed to help keep you in range.
Diabetes care is highly personalized, and Garzulys was approved with multiple ways to take it. Depending on your prescription and lifestyle, Garzulys can be administered:
The medication is available in two convenient formats: a 10-mL multiple-dose vial and a prefilled 3-mL pen (both in the standard U-100 strength).
This is a common question at the pharmacy counter. While Garzulys is highly similar to NovoLog, it is currently approved as a biosimilar, not an interchangeable product.
This simply means that your pharmacist cannot automatically swap your NovoLog prescription for Garzulys without checking with your doctor first. If you and your healthcare provider decide Garzulys is a good fit—perhaps because it is better covered by your insurance—your doctor will need to write a specific prescription for Garzulys.
A new insulin approval is always good news for the diabetes community. More options often lead to more competitive pricing, better insurance coverage, and ultimately, easier access to life-saving medications.
If you currently use NovoLog or another mealtime insulin and are looking for different options, Garzulys might be worth bringing up at your next check-up. As always, never make changes to your insulin regimen without talking to your healthcare team first.
Sources Used: